FDA Recalls Oxytocin Injectable Bags Due to Sterility Assurance Failure
FDA recalls 2,989 bags of oxytocin mixed with Lactated Ringer's solution nationwide due to lack of sterility assurance. An FDA inspection raised questions about whether the injectable drug met sterility standards.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable pharmaceutical product where sterility assurance could not be confirmed. No illnesses or injuries have been reported. This meets the rubric criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 2,989 bags of oxytocin 10 units added to Lactated Ringer's 500 mL solution due to lack of assurance of sterility. The recall was initiated following an FDA inspection that raised questions about whether the products met required sterility standards for injectable pharmaceuticals.
Oxytocin is a hormone used in medical settings. Lactated Ringer's solution is an intravenous electrolyte replacement fluid. Both products are intended to be sterile for injection. If not sterile, patients could be exposed to microbial contamination.
The affected product was distributed nationwide. The recalled lots include: 37-891283 (Exp 05/06/2023), 37-892501 (Exp 05/12/2023), 37-894413 (Exp 05/19/2023), 37-896228 (Exp 05/26/2023), 37-896815, 37-896820, 37-896826 (Exp 05/28/2023), and 37-900126 (Exp 06/10/2023).
Healthcare facilities and healthcare providers should discontinue use of the recalled product immediately. Patients who have received these products should consult their healthcare provider. For recall information, contact Central Admixture Pharmacy Services, Inc. at 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106.
The recalled product
- Product
- oxyTOCIN 10 units added to Lactated Ringer's 500 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 72185-6036-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Intravenous / Injectable
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (14)
- Lot # 37-891283
- Exp 05/06/2023
- 37-892501
- Exp 05/12/2023
- 37-894413
- Exp 05/19/2023
- 37-896228
- Exp 05/26/2023
- 37-896815
- 37-896820
- 37-896826
- Exp 05/28/2023
- 37-900126
- Exp 06/10/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27